Paper39384609
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma.
Sidana S and 20 others. Blood Cancer J, 2024. Cited by 7 papers, by iCite.
Cite this record
ConductScience Library. Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma. Papers, record 39384609. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39384609
- Disease
- plasma cell myeloma553 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Benzylamines | Major topic |
| Cyclams | Major topic |
| Hematopoietic Stem Cell Mobilization | Major topic |
| Heterocyclic Compounds | Major topic |
| Multiple Myeloma | Major topic |
| Receptors, Interleukin-8B | Major topic |
| Adult | |
| Aged | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Hematopoietic Stem Cell Transplantation |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| KL2TR003143 | NIH | NIH RePORTER | |||
| S10RR027582 | NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04552743 | MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma | Derived from the trial | Yes |
Source ClinicalTrials.gov
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15042106 | The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. | Leukemia | 2004 | https://conductscience.org/library/papers/15042106 | PubMed |
| 2 | 30160591 | Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study. | Leuk Lymphoma | 2019 | https://conductscience.org/library/papers/30160591 | PubMed |
| 3 | 19363221 | Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. | Blood | 2009 | https://conductscience.org/library/papers/19363221 | PubMed |
| 4 | 10725737 | Identification of unique truncated KC/GRO beta chemokines with potent hematopoietic and anti-infective activities. | J Immunol | 2000 | https://conductscience.org/library/papers/10725737 | PubMed |
| 5 | 21131166 | Using confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI). | J Pain Symptom Manage | 2011 | https://conductscience.org/library/papers/21131166 | PubMed |
| 6 | 33915323 | Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. | Transplant Cell Ther | 2021 | https://conductscience.org/library/papers/33915323 | PubMed |
| 7 | 15160937 | CD34+ CD90+ cells and late hematopoietic reconstitution after autologous peripheral blood stem cell transplantation. | Leuk Lymphoma | 2004 | https://conductscience.org/library/papers/15160937 | PubMed |
| 8 | 21042307 | Outcome, toxicity profile and cost analysis of autologous stem cell mobilization. | Bone Marrow Transplant | 2011 | https://conductscience.org/library/papers/21042307 | PubMed |
| 9 | 29093179 | A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates. | Sci Transl Med | 2017 | https://conductscience.org/library/papers/29093179 | PubMed |
| 10 | 17581613 | Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. | Leukemia | 2007 | https://conductscience.org/library/papers/17581613 | PubMed |
| 11 | 24141007 | Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. | Biol Blood Marrow Transplant | 2014 | https://conductscience.org/library/papers/24141007 | PubMed |
| 12 | 24185588 | Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy. | Bone Marrow Transplant | 2014 | https://conductscience.org/library/papers/24185588 | PubMed |
| 13 | 30742126 | Proliferation tracing with single-cell mass cytometry optimizes generation of stem cell memory-like T cells. | Nat Biotechnol | 2019 | https://conductscience.org/library/papers/30742126 | PubMed |
| 14 | 32442725 | Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. | Biol Blood Marrow Transplant | 2020 | https://conductscience.org/library/papers/32442725 | PubMed |
| 15 | 18158968 | Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. | Biol Blood Marrow Transplant | 2008 | https://conductscience.org/library/papers/18158968 | PubMed |
| 16 | 7595706 | Factors that influence collection and engraftment of autologous peripheral-blood stem cells. | J Clin Oncol | 1995 | https://conductscience.org/library/papers/7595706 | PubMed |
| 17 | 31502160 | High-Parameter Immune Profiling with CyTOF. | Methods Mol Biol | 2020 | https://conductscience.org/library/papers/31502160 | PubMed |
| 18 | 17324341 | AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma. | Clin Lymphoma Myeloma | 2007 | https://conductscience.org/library/papers/17324341 | PubMed |
| 19 | 32010993 | Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. | Am J Hematol | 2020 | https://conductscience.org/library/papers/32010993 | PubMed |
| 20 | 37708911 | Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. | Lancet Haematol | 2023 | https://conductscience.org/library/papers/37708911 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41954299 | CXCL12/CXCR4 axis in neuropathic pain: Insights from preclinical models and translational implications. | Mol Pain | 2026 | https://conductscience.org/library/papers/41954299 | PubMed |
| 41688740 | Metabolic crosstalk among cancer-associated fibroblasts, adipocytes and immune cells as an immunosuppressive tumor microenvironment driver. | Exp Mol Med | 2026 | https://conductscience.org/library/papers/41688740 | PubMed |
| 40932993 | GroβT rapidly and reliably mobilizes primitive hematopoietic stem and progenitor cells in nonhuman primates. | Mol Ther Methods Clin Dev | 2025 | https://conductscience.org/library/papers/40932993 | PubMed |
| 40656546 | Cancer-Associated Fibroblasts: Heterogeneity, Cancer Pathogenesis, and Therapeutic Targets. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40656546 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD34 | 947 | PubTator's text mining | https://conductscience.org/library/genes/947 | NCBI Gene |
| CD38 | 952 | PubTator's text mining | https://conductscience.org/library/genes/952 | NCBI Gene |
| CXCR2 | 3579 | PubTator's text mining | https://conductscience.org/library/genes/3579 | NCBI Gene |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| PLERIXAFOR | CHEMBL18442 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL18442 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39384609
GET https://conductscience.org/api/papers/v1/39384609/authors?page=2